1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sanofi Consumer Healthcare India Limited

Sanofi Consumer Healthcare India Limited

3,207.60
INR
-56.40
(-1.73%)
115.49EPS
40.05P/E
106.52BMarket Cap
Nov 18Next Earn
Sanofi Consumer Healthcare India Limited
BSE:SANOFICONR
(Bombay Stock Exchange)

Recent

price

3,207.60

P/E

ratio

40.05

div

yld

- -

ROIC.AI

2023
2024
2025
TTM
INR
236.34
310.98
381.23
412.38
Revenue per Share
71.6
78.59
104.25
115.49
Basic EPS, GAAP
-1.91
186.32
72.6
- -
Free Cash Flow per Basic Share
- -
50.02
55.01
- -
Dividend per Share
90.14
118.54
166.73
151.06
Book Value per Share
87.75
117.71
166.39
150.93
Tangible Book Value per Share
23
23
23
23
Basic Weighted Avg Shares
5,443
7,162
8,780
9,498
Sales/Revenue/Turnover
39.9
37.17
33.87
35.77
Operating Margin (%)
18
45
117
132
Depreciation Expense
1,649
1,810
2,401
2,660
Net Income, GAAP
24.81
26.66
25.04
25.53
Effective Tax Rate (%)
30.3
25.27
27.35
28.01
Profit Margin (%)
2,053
2,611
3,659
3,363
Working Capital
- -
166
171
128
LT Debt
2,076
2,730
3,840
3,479
Total Equity
- -
63.2
65.12
76.56
Return on Invested Capital (%)
- -
73.44
68.84
81.8
Return on Capital (%)
- -
75.32
73.09
87.95
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
77
- -
80
LT Borrowings
- -
- -
- -
LT Finance Leases
171
- -
128
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
104,245
98,893
106,519

Working Capital

INR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,943
- -
6,634
Cash, Cash Equivalents & STI
3,752
- -
4,923
Accounts Receivable, Net
296
- -
498
Inventories
619
- -
937
Total Current Liabilities
1,284
- -
3,271
Payables & Accruals
- -
- -
- -
ST Debt
77
- -
80
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
40.66%
Free Cash Flow
- -
- -
-61.03%
Net Income, GAAP
- -
- -
32.65%
Sales/Revenue/Turnover
- -
- -
22.59%
Total Cash Common Dividend
- -
- -
9.98%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,216
1,723
1,599
1,707
7,162
2025
1,726
2,209
2,339
2,510
8,780
2026
2,292
2,357
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
27.22
12.59
19.52
19.25
78.59
2025
21.69
26.36
27.31
28.87
104.25
2026
29.44
29.87
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
50.02
2025
- -
- -
- -
- -
55.01
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sanofi Consumer Healthcare India Ltd. (SANOFICONR.NS) operates as the Indian subsidiary of Sanofi, focusing on the development, manufacturing, marketing, and distribution of consumer healthcare products including over-the-counter medicines, vitamins, minerals, supplements, and personal care items such as allergy remedies (e.g., Allegra), pain relief (e.g., Combiflam), digestive health solutions (e.g., Enterogermina), cough and cold treatments (e.g., Strepsils), skin care (e.g., Cetaphil), and women's health products (e.g., Combipatch). The company serves retail consumers, pharmacies, and healthcare professionals across India, with a presence in urban and rural markets through an extensive distribution network. Founded as part of Sanofi's global consumer healthcare division (established in 2019 following the spin-off from Sanofi proper), it is headquartered in Mumbai, India, and operates nationwide with manufacturing facilities supporting local production. In recent developments within the last 1-2 years, Sanofi Consumer Healthcare has expanded its portfolio through new product launches tailored to Indian consumers, including enhanced formulations in respiratory health and immunity boosters amid post-pandemic demand; it has also strengthened strategic partnerships with local distributors and e-commerce platforms like Amazon India and Flipkart to boost accessibility. The parent Sanofi group announced the sale of its India consumer healthcare business to Nova Nordisk in early 2025, marking a significant divestiture to refocus on pharmaceuticals, though operational continuity persists under transition; additionally, Sanofi introduced sustainability initiatives in packaging and supply chain for its Indian operations in 2024. These changes align with broader segment shifts in the consumer healthcare industry, emphasizing digital sales channels and localized innovation.